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Abstract  
BACKGROUND: Leptomeningeal metastases are diagnosed in 1% to 8% of patients with cancer. 
The most common histology is leukaemia, lymphoma, breast carcinoma, lung carcinoma and 
melanoma. The aim of this study is to show the appearance of leptomeningeal metastases in lung 
and breast cancer with specific biological features. 
AIM: The study is a review of two cases - breast and lung carcinoma with specific biological 
features who eventually have developed leptomeningeal metastases. 
CASE PRESENTATION: Although CNS metastasis most commonly occurs in those with known 
systemic metastases, our patient had biological indolent disease (nor hormone negative or HER 2 
positive and no metastatic disease) and still LM did occur. LM remains a devastating complication 
of cancer with classic presentation with multifocal neurologic signs and symptoms (like the case 
with lung cancer), but many patients also have evidence of impaired CSF flow, and hydrocephalus 
may be the only presenting manifestation of LM. 
CONCLUSION: The prognostic factors associated with survival in patients with LM metastasis are 
not certain as well as right treatment for these patients which is still a big challenge. Due to the lack 
of randomized studies and especially of studies referring to one specific primary tumor, there is 
currently no generally accepted standard of care in the treatment of LM metastases. 
 
 
 
Introduction 
 
Autopsy studies have shown that 
leptomeningeal metastases (LM) are diagnosed in 1% 
to 8% of patients with cancer [1]. Many types of 
tumors have been reported, but the most common 
histology are leukemia, lymphoma, breast carcinoma, 
lung carcinoma and melanoma. LM manifest as a 
multifocal constellation of neurologic signs and 
symptoms, although occasionally patients present 
only with evidence of hydrocephalus or elevated 
intracranial pressure. The location of the signs and 
symptoms can be divided into three anatomic 
compartments: the cerebral hemispheres, the 
posterior fossa/cranial nerves, and spinal cord/nerve 
roots, and any or all of compartments may be 
involved. Despite the improvement of the sensitivity of 
diagnostic techniques, the diagnosis of LM remains 
challenging, and neither cerebrospinal fluid (CSF) 
cytology nor MRI is adequately sensitive to be used in 
isolation. MRI has consistently been highly sensitive 
for the diagnosis of LM from solid tumors, with 
sensitivity ranging from 76 % to 100% [1], but it is less 
sensitive for hematopoietic tumors. MRI should 
generally be performed before lumbar puncture for 
CSF analysis, because pachymeningeal 
enhancement can be seen after lumbar puncture if 
intracranial hypotension develops [1], so the contrast-
enhanced magnetic resonance imaging has emerged 
as a reliable diagnostic tool in LM and in the 
appropriate clinical context, findings suggestive of LM 
on MRI are adequate to initiate treatment of LM even 
in the absenace of positive CFS cytology [2]. Positive 
CSF is pathognomonic for LM, but its sensitivity is 
limited.  
A review of the literature encompassing 
multiple series totaling more than 500 patients led to 
the calculation of 71% sensitivity for an initial cytology 
sample. The sensitivity increased to 86% after two 
samples, to 90% after three samples, and 93% after 
more than three samples [3]. Even in those with 
negative cytology, CSF pleocytosis, elevated protein, 
and hypoglycorrhachia are common and provide 
supportive evidence for the diagnosis of LM. More 
specialized CSF tests can also be useful in certain 
situations like flow cytometry in hematopoietic 
malignancies. Variety of other biochemical markers 
have also been studied in patients with LC but their 
use has poor sensitivity and specificity (i.e. 
lymphocytes in CSF can also be characterized to see 
whether they are T cells or B cells, specific tumor 
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markers – CEA etc). Chemotherapy and radiotherapy 
for treatment of LM metastasis have been used in 
different modalities. Basically, the poor results 
achieved with current modalities led to the 
controversial management of these patients and the 
big importance is that any treatment decision should 
be based on which patient is most likely to benefit 
from it.  
The aim of this study is to show the 
appearance of leptomeningeal metastases in lung and 
breast cancer with specific biological features.  
 
 
Case Reports 
 
The study is a review of two cases:  
First case: This is a case about 35 years old 
female patient with a history of right breast carcinoma. 
The disease began 3 years ago (2010). She had been 
diagnosed with stage IIIC invasive ductal carcinoma; 
(ER+, PR+, HER2-), with lymphovascular invasion 
and positive axillary nodes as well as positive 
ipsilateral supraclavicular node after total mastectomy 
with axillary dissection. The patient was treated with 
neoadjuvant chemotherapy (four cycles of doxorubicin 
and cyclophosphamide followed by four cycles of 
paclitaxel). After the surgery radiation therapy was 
proceed (TTD = 50 Gy/25 fr) followed with hormone 
therapy with tamoxifen. During the treatment the 
patient was complained of strong headache which 
didn’t respond to acetaminophen or ibuprofen. The 
conciliar neurologist was consulted and MRI was 
recommended. MRI demonstrated several 
parenchymal metastases, the largest of which was in 
the left cerebellar hemisphere, as well as extensive 
leptomeningeal enhancement most evident in the 
posterior fossa, around the brainstem. Lumbar 
puncture 3 days later revealed positive cytology 
demonstrating numerous malignant cells compatible 
with her known breast carcinoma, confirming the 
diagnosis of leptomeningeal metastasis. The 
neurologic symptoms rapidly worsened so the patient 
was put on anti-edematous and antiepileptic therapy.  
Second case: This is the case about patient 
60 years old man. The first symptoms of disease have 
occurred in 2011. He had been diagnosed with stage 
IIIA (T3N2M0, EGFR-) adenocarcinoma of the right 
lung with metastasis to the ipsilateral mediastinal 
lymph nodes. He was treated neoadjuvantly 
(cisplatin/etoposide) followed by lobectomy and 
selective lymph node dissection. After the operation 
radiotherapy was performed (TTD = 60 Gy). The 
patient has disease free interval of two years and then 
he developed focal left arm seizure. MRI was 
recommended and showed a right posterior frontal 
parenchymal brain metastasis. Systemic restaging 
was negative, and whole brain radiation was 
recommended (TTD = 30 Gy). The chemotherapy 
(carboplatin/paclitaxel for 4 courses) was started. 
After one year he developed focal midthoracic back 
pain and was found to have Th8 vertebral metastasis 
that was radiated (TTD = 8 Gy/1fr). The patient was 
put on bisphosphonate therapy (amp. Zolendronic 
acid/4 mg). After six mounts he developed a 
progressive right facial droop with increasing bilateral 
lower extremity weakness followed by urinary 
incontinence. Another MRI of the brain and spine was 
done. There were three small superficial parenchymal 
brain metastases, but no lesions that would explain 
his symptoms. The neurologist was consulted and he 
recommended lumbar puncture. Lumbar puncture was 
performed and cytology revealed malignant cells 
which confirmed the diagnosis of leptomeningeal 
metastasis. The patient general condition was limiting 
for further specific therapy so he was recommended 
symptomatic therapy.  
 
Figure 1: Axial T1 – weighted MRI indicating a parenchymal brain 
metastasis (image A) as well as leptomeningeal enchancement 
coating the brainstam (image A) and cerebellar folia (image B), 
consistent with leptomeningeal metatstatis. 
 
 
Discussion 
 
Carcinomatous meningitis arises from either 
solid tumors or haematological malignancies. During 
the past few decades the incidence of LC 
(leptomeningeal carcinomatosis) appears to be 
increasing as imaging studies improve and as cancer 
patients live longer. Overall, neoplastic meningitis 
occurs in 5–8% of patients with cancer, whereas 
almost 20% of patients with neurological symptoms 
and signs are found to have LC during autopsy. 
Among solid tumors adenocarcinoma is the most 
predominant histological type. LC is more frequently 
seen in widely disseminated and progressive disease. 
The interval between initial cancer diagnosis and the 
development of LM is longer for breast cancer than in 
other solid tumors. Median time from initial breast 
cancer diagnosis to LM is 3 ½ years [4], compared to 
one year or less for lung cancer [5].  
Breast cancer is the most common solid 
tumor complicated by LC and accounts for 11–64% of 
all cancer patients, but only 5% of patients with breast 
cancer. Brain metastases in breast cancer occur most 
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commonly (10%) in the young adults (20-39 years-old) 
[6] – 35 years in our case report. CNS metastasis in 
breast cancer may present long after treatment of the 
primary cancer [7], but in some situations depending 
of other factors they can present during the treatment 
of primary disease (like our case with breast cancer). 
Although CNS metastasis most commonly occurs in 
those with known systemic metastasis, the overall risk 
of CNS recurrence as the initial site of metastatic 
spread is 1.3% and certain breast cancer subtypes 
have been associated with an increased risk of CNS 
metastasis [8]. Initial hormone receptor positivity is 
associated with higher incidence of bone metastasis 
and a longer median time to development of LM when 
compared to triple-negative breast cancer [9]. Triple 
negative breast cancer is more likely than receptor 
positive breast cancer to present with isolated LM and 
has been associated with a shorter median overall 
survival following the development of distant 
metastases. One study of a 3 year median follow-up 
of triple negative breast cancer patients 36% had CNS 
involvement in their clinical course [10]. Our patient 
had biological indolent disease (nor hormone negative 
or HER 2 positive and no metastatic disease) and still 
LM did occur. HER-2 status does not appear to impact 
overall survival from LM, but it is important to notice 
that the treatment with target therapy – trastuzumab 
was associated with a significantly longer time to the 
development of LM metastases (15.2 v.s 9.9 months) 
[11].  
Lung cancer accounts for 14–29% of all 
cancer patients, but only 9–25% of patients with LC. 
The clinical features and prognostic factors of LC in 
NSCLC patients, however, have not been well 
identified [12]. LM remains a devastating complication 
of cancer with classic presentation with multifocal 
neurologic signs and symptoms (like the case with 
lung cancer), but many patients also have evidence of 
impaired CSF flow, and hydrocephalus may be the 
only presenting manifestation of LM. Relief of CSF 
outflow obstruction by CSF diversion has been shown 
to improve functional status, and is likely to prolong 
survival in these cases [13].  
The prognostic factors associated with 
survival in patients with LM metastasis are not certain 
[14]. The study conducted at M. D. Anderson Cancer 
Center has reviewed the records from treated patients 
with LM metastasis between 1944 and 2002. The 
primary hypothesis was that more extensive burden of 
CNS metastasis at the time of diagnosis of LM (as 
evidenced by imaging of the CNS parenchyma and 
meninges and CSF cytology status (positive versus 
negative) correlates with poorer outcomes. The study 
has showed that the amount of CNS tumor burden at 
the time of diagnosis of LM did not inversely correlate 
with survival outcomes. Another question that is still 
open is the right treatment for these patients and it is 
still a big challenge. Due to the lack of randomized 
studies and especially of studies referring to one 
specific primary tumor, there is currently no generally 
accepted standard of care in the treatment of LM 
metastases. Surgery (for hydrocephalus), radiation 
therapy (RT), and chemotherapy (systemic or intra-
CSF) may be considered. Treatment decisions are 
influenced by the individual’s functional status, ability 
and willingness to receive additional treatment, and 
extent of active systemic disease. In some cases, the 
diagnosis of LM compels providers and patients to 
pursue palliative care, especially when LM is 
accompanied by a dramatic clinical decline. Working 
with currently available therapies, aggressive ICP 
management and combination IT chemotherapy may 
afford some survival benefit over previously studied IV 
or IT monotherapies [15]. Intra – CSF (intralumbar or 
IT and IVent) chemotherapy is the mainstay of 
treatment for LM, although its superiority compared 
with systemic treatment has not been established in 
randomized trials and its efficacy consequently is 
uncertain [16]. Nevertheless, recent retrospective data 
suggested that intra-CSF chemotherapy may have 
utility in NSCLC patients [16]. Among new generation 
chemotherapeutic agents, several studies have 
suggested that in patients with NSCLC and LM 
metastases may benefit from EGFR target therapy 
[17] on the other hand aggressive chemotherapy has 
resulted in improved outcomes for patients with LM in 
breast cancer [18].  
Despite advances in the treatment of cancer 
in general, survival for patients with LM remains 
dismal. Prospective studies have found a median 
overall survival (OS) of 9-30.3 weeks in those with 
breast cancer following the diagnosis of LM. 
Compared to lung cancer LM, studies have shown 
mixed results, with some favoring a longer survival for 
breast cancer LM and others demonstrating no 
difference.  
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